Related Experiment Video

Updated: Aug 20, 2026

Studying the Hypothalamic Insulin Signal to Peripheral Glucose Intolerance with a Continuous Drug Infusion System into the Mouse Brain
08:32

Studying the Hypothalamic Insulin Signal to Peripheral Glucose Intolerance with a Continuous Drug Infusion System into the Mouse Brain

Published on: January 4, 2018

An observational study comparing continuous subcutaneous insulin infusion (CSII) and insulin glargine in children

Riccardo Schiaffini1, Paolo Ciampalini, Sabrina Spera

  • 1Unit of Endocrinology, Bambino Gesù Children's Hospital, Research Institute, Rome, Italy.

Diabetes/Metabolism Research and Reviews
|December 25, 2004
PubMed

Insights

Continuous subcutaneous insulin infusion (CSII) significantly improved glycemic control in children with type 1 diabetes compared to insulin glargine. CSII reduced HbA1c and insulin requirements, offering a superior intensive treatment approach.

Area of Science:

  • Pediatric Endocrinology
  • Metabolic Disorders
  • Diabetes Management

Background:

  • Continuous subcutaneous insulin infusion (CSII) and insulin glargine are effective in managing diabetes in adults and children.
  • Limited comparative data exists for these intensive approaches in pediatric populations.

Purpose of the Study:

  • To compare the efficacy of CSII versus insulin glargine in children with type 1 diabetes.
  • To evaluate glycemic control and insulin requirements in pediatric patients.

Main Methods:

  • Retrospective analysis of 36 children with type 1 diabetes and HbA1c >8.0%.
  • Twenty patients transitioned to CSII, while 16 started bedtime insulin glargine.
  • Data analyzed at 6 and 12 months post-intervention.

Main Results:

  • CSII significantly reduced HbA1c from 8.5% to 7.4% at 6 months and 7.6% at 12 months.
  • Insulin requirements decreased significantly with CSII (0.93 to 0.73 IU/kg).
  • Insulin glargine showed a non-significant HbA1c reduction (8.9% to 8.2%).

Conclusions:

  • Both CSII and insulin glargine effectively provide basal insulin supplementation in pediatric type 1 diabetes.
  • CSII is confirmed as the optimal intensive approach for improving glycemic control in children, aligning with adult findings.
Abstract

More Related Videos

Improving IV Insulin Administration in a Community Hospital12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

Related Concept Videos

Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Insulin Formulations: Types and Delivery01:27

Insulin Formulations: Types and Delivery

Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into rapid-acting...
Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type I Diabetes I: Introduction01:12

Type I Diabetes I: Introduction

Type 1 diabetes mellitus is a chronic metabolic disorder characterized by an absolute deficiency of insulin resulting from the autoimmune destruction of pancreatic β-cells. Although it can occur at any age, it is most commonly diagnosed in childhood, adolescence, or early adulthood. The loss of insulin production impairs cellular glucose uptake, resulting in persistent hyperglycemia and necessitating lifelong insulin therapy.Autoimmune Destruction of β-CellsThe hallmark of type 1 diabetes is an...
Type I Diabetes II: Pathophysiology01:26

Type I Diabetes II: Pathophysiology

Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...
Type I Diabetes III: Clinical Manifestations01:19

Type I Diabetes III: Clinical Manifestations

Type 1 diabetes mellitus typically presents with rapid-onset symptoms due to the body’s inability to utilize glucose in the absence of insulin. Since insulin is required for glucose uptake into cells, its deficiency leads to hyperglycemia and cellular energy deprivation, resulting in characteristic clinical features.Polyuria and PolydipsiaOne of the earliest, most prominent symptoms is polyuria (excessive urination). When blood glucose concentrations rise above the renal threshold, the kidneys...